Clear Harbor Asset Management LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 124.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 5,421 shares of the biopharmaceutical company’s stock after acquiring an additional 3,006 shares during the quarter. Clear Harbor Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $3,862,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in REGN. AE Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 19.4% in the 2nd quarter. AE Wealth Management LLC now owns 547 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 89 shares during the period. Pacer Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 9.5% in the second quarter. Pacer Advisors Inc. now owns 16,464 shares of the biopharmaceutical company’s stock worth $17,304,000 after buying an additional 1,434 shares in the last quarter. Sei Investments Co. raised its position in shares of Regeneron Pharmaceuticals by 2.2% in the 2nd quarter. Sei Investments Co. now owns 24,944 shares of the biopharmaceutical company’s stock worth $26,214,000 after acquiring an additional 537 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 28.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 5,657 shares of the biopharmaceutical company’s stock valued at $5,946,000 after buying an additional 1,263 shares during the last quarter. Finally, Frank Rimerman Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 19,133.3% in the 2nd quarter. Frank Rimerman Advisors LLC now owns 577 shares of the biopharmaceutical company’s stock worth $606,000 after purchasing an additional 574 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.
Regeneron Pharmaceuticals Trading Down 1.7 %
Shares of REGN opened at $681.58 on Tuesday. The firm’s fifty day moving average is $738.60 and its two-hundred day moving average is $948.80. The stock has a market cap of $74.90 billion, a PE ratio of 16.87, a price-to-earnings-growth ratio of 1.61 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $666.25 and a 52-week high of $1,211.20.
Analysts Set New Price Targets
View Our Latest Report on Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
Recommended Stories
- Five stocks we like better than Regeneron Pharmaceuticals
- What is a SEC Filing?
- Transports Are Trending Higher: It’s a Golden Time to Buy More
- How to Calculate Return on Investment (ROI)
- A Hidden Winner in Manufacturing and Energy Set for a Breakout
- Dividend Payout Ratio Calculator
- Beyond Rigetti: Top 3 Quantum Computing Stock Picks
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.